Percutaneous balloon valvuloplasty for bioprosthetic mitral valve stenosis

Hamatani, Yasuhiro; Saito, Naritatsu; Tazaki, Junichi; Natsuaki, Masahiro; Nakai, Kentaro; Makiyama, Takeru; Sasaki, Yasuhiro; Imai, Michitaka; Watanabe, Shin; Shioi, Tetsuo; Kimura, Takeshi; Inoue, Kanji

doi:10.1007/s00380-012-0309-7

Cited by 11 publications

(8 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Percutaneous transcatheter balloon valvuloplasty for bioprosthetic TV stenosis is not performed as often as it is in other bioprosthetic valves. 16 Herein we present reports of 3 cases performed at our hospital and a comprehensive compilation of previously reported cases of this procedure. Bioprosthetic valve dysfunction or obstruction usually results from leaflet calcification, thrombosis, pannus ingrowth, or vegetation.…”

Section: Discussionmentioning

confidence: 99%

Percutaneous Valvuloplasty for Bioprosthetic Tricuspid Valve Stenosis

Rana¹,

Malhotra²,

Sharma³

et al. 2017

Texas Heart Institute Journal

View full text Add to dashboard Cite

Percutaneous transcatheter tricuspid balloon valvuloplasty (PTTBV) is an accepted treatment option for symptomatic severe native tricuspid valve stenosis, although surgical tricuspid valve replacement remains the treatment of choice. There have been few reports of successful PTTBV for bioprosthetic tricuspid valve stenosis. We present case reports of 3 patients from our hospital experience. Two of the 3 cases were successful, with lasting clinical improvement, whereas the 3rd patient failed to show a reduction in valve gradient. We describe the standard technique used for PTTBV. We present results from a literature review that identified 16 previously reported cases of PTTBV for bioprosthetic severe tricuspid stenosis, with overall favorable results. We conclude that PTTBV should perhaps be considered for a select patient population in which symptomatic improvement and hemodynamic stability are desired immediately, and particularly for patients who are inoperable or at high surgical risk.

show abstract

Section: Discussionmentioning

confidence: 99%

Percutaneous Valvuloplasty for Bioprosthetic Tricuspid Valve Stenosis

Rana¹,

Malhotra²,

Sharma³

et al. 2017

Texas Heart Institute Journal

View full text Add to dashboard Cite

show abstract

“…There have been limited reports of successful procedures of balloon valvuloplasty for bioprosthetic mitral valve stenosis. However, there is a need for prospective studies to assess the efficacy and durability of this procedure [62,63] .…”

Section: Pmv In Patients With Stenosed Mitral Bioprosthesismentioning

confidence: 99%

Percutaneous mitral balloon valvuloplasty - state of the art

Palacios¹

2020

Mini-invasive Surg

View full text Add to dashboard Cite

Since its introduction in 1982, percutaneous mitral balloon valvuloplasty (PMV) has been used successfully as an alternative to open or closed surgical mitral commissurotomy in the treatment of patients with symptomatic rheumatic mitral stenosis. PMV is safe and effective and provides sustained clinical and hemodynamic improvement in patients with mitral stenosis. The immediate and long-term results appear to be similar to those of surgical mitral commissurotomy. Proper patient selection is an essential step for being able to predict the immediate results of PMV. Candidates for PMV require precise assessment of the mitral valve morphology. The Wilkin's echocardiographic score (Echo-Sc) is currently the most widely used method for predicting PMV outcome. Leaflet mobility, leaflet thickening, valvular calcification, and sub valvular disease are each scored from 1 to 4. An inverse relationship exists between the Echo-Sc and PMV success. Both immediate and intermediate follow-up studies have shown that patients with Echo-Sc ≤ 8 have superior results, significantly greater survival, and event free survival compared to patients with Echo-Sc > 8. We identified other clinical and morphologic predictors of PMV success that include age, pre-PMV mitral valve area, history of previous surgical commissurotomy, and mitral regurgitation (MR), and post-PMV variables (e.g., post-PMV MR ≥ 3 + and pulmonary artery pressure), that may be used in conjunction with the Echo-Sc to optimally identify candidates for PMV. This concept demonstrates a multifactorial nature of the prediction of immediate and long-term results. Other echocardiographic scores have been developed for the screening of potential candidates for PMV. They include a unique score that take into account the length of the chordae. A novel quantitative score that included the ratio of the commissural areas over the maximal excursion of the leaflets from the annulus in diastole. The components of this score include mitral valve area ≤ 1 cm 2 , maximum leaflet displacement ≤ 12 mm, commissural area ratio ≥ 1.25, and sub valvular involvement. Finally, a score that is able to identify patients who are more

show abstract

“…Rheumatic mitral stenosis (MS) is an important cause of valvular heart disease, which is commonly treated by interventional (PBMV) [1,2] or surgical valvotomy. Alternatively, valve surgery can be performed by implanting an MP [3].…”

Section: Introductionmentioning

confidence: 99%

Echocardiographically derived effective valve opening area in mitral prostheses: a comparative analysis of various calculations using continuity equation and pressure half time method

et al. 2015

View full text Add to dashboard Cite

Detection of dysfunctional mitral valve prostheses (MP) remains complex even though being optimized by considering echocardiographically derived prosthetic effective orifice area (VA). The purpose was to compare VA in MP, calculated by the continuity equation (CE) using peak velocities (CEVpeak), mean velocities (CEVmean), velocity-time integrals (CEVTI) and the pressure half time method using 220 ms as constant first (PHT220) as well as optimized constants. In 267 consecutive patients with normally functioning MP, we investigated VA within the first postoperative month. With increasing prosthetic sizes, mean VA values also increase in all calculations. The statistical curves demonstrate no significant difference in graphical steepness but show different levels. Comparison of mean VA showed the known systematic higher values of PHT220 and significantly decreased results when using CEVTI. This systematic difference between mean VA applying PHT220 versus CEVTI is approximately 1.0 cm(2) for all prosthetic sizes. Calculations via CEVpeak were close to the results of CEVTI. CEVmean produced values, which graphically correspond to the PHT220 curve. Only PHT220 detected the constructional equal prosthetic inner ring width between 29 and 31 mm. To compensate the systematic difference between CEVTI and PHT220, an optimized constant of 140 ms was calculated to be applied in PHT (PHT140). VA is a robust and, therefore, preferable parameter for investigating MP. If needed, both CE and PHT are applicable with a systematical difference between CEVTI and PHT220. An optimized constant of 140 ms (PHT140) should be applied when calculating VA of mitral valve prostheses via PHT.

show abstract

Percutaneous balloon valvuloplasty for bioprosthetic mitral valve stenosis

Cited by 11 publications

References 27 publications

Percutaneous Valvuloplasty for Bioprosthetic Tricuspid Valve Stenosis

Percutaneous Valvuloplasty for Bioprosthetic Tricuspid Valve Stenosis

Percutaneous mitral balloon valvuloplasty - state of the art

Echocardiographically derived effective valve opening area in mitral prostheses: a comparative analysis of various calculations using continuity equation and pressure half time method

Contact Info

Product

Resources

About